Menu
Our strengths
Facilities and ressources
Partners
Scientific and medical environment
Equipment
Network
Antineo’s strengths are:
An exceptional access to cutting-edge technologies and equipment
A dedicated and reactive team of scientists
About Us
Antineo
Our Team
Our scientific commitee
Mission and Vision
Preclinical services in oncology
in vitro
preclinical services
Preclinical development of immunotherapies
Preclinical development in vitro end point studies
In vitro cytotoxicity
In vitro synergy assays
Cell cycle, proliferation, apoptosis
Multiple colour flow cytometry
Immunology and Immuno-Oncology
Preclinical Development in vitro continuous-monitoring studies
xCELLigence
IncuCyte
Preclinical tumour models
Original preclinical resistant tumour models
Sample Characterisation
Multiple colour flow cytometry
Molecular Biology
High throughput sequencing
ex vivo
preclinical services
in vivo
preclinical services
Preclinical non-reglementary toxicity
Preclinical non-reglementary pharmacokinetics
Preclinical tumour models
Resistant preclinical tumour models
Preclinical in vivo efficacy studies
Tumour and organ sampling
Preclinical development
of immunotherapies
Immunology and Immuno-oncology
Antibody dependant mechanisms
in vivo ADCC assay
in vivo CDC assay
in vivo efficacy study for
bispecific antibodies
Preclinical tumour models
Cell-Derived Xenografts
Solid tumours preclinical xenograft models
Liquid tumours preclinical xenograft models
Syngeneic mice tumour models
Liquid tumours preclinical syngeneic models
Solid tumours preclinical syngeneic models
Original preclinical resistant tumour models
Patient-Derived Xenografts
Our strengths
Facilities and ressources
Scientific and medical environment
Equipment
Network
Partners
Contact
News
Publications
